The African-specific S47 polymorphism of p53 alters chemosensitivity

Cell Cycle

Volumn 15, Issue 19, 2016, Pages 2557-2560

  Basu, Subhasree ^a   Barnoud, Thibaut ^a   Kung, Che Pei ^b   Reiss, Matthew ^a   Murphy, Maureen E ^a  

^a WISTAR INSTITUTE   (United States)

^b USA   (United States)

Author keywords

chemosensitivity; cisplatin; ferroptosis; Gls2; Pro47Ser; Sco2

Indexed keywords

CASPASE 3; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; DOXORUBICIN; E1A PROTEIN; PACLITAXEL; PROTEIN MDM2; PROTEIN P53; RAS PROTEIN; ANTINEOPLASTIC AGENT; ERASTIN; PIPERAZINE DERIVATIVE;

AFRICAN; ANIMAL CELL; APOPTOSIS; CANCER RESISTANCE; CELL CLONE; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOTOXICITY; DNA POLYMORPHISM; EMBRYO; HUMAN; HUMAN CELL; IC50; MOUSE; NONHUMAN; NOTE; PROTEIN CLEAVAGE; TRANSACTIVATION; TRANSFORMED CELL; ANIMAL; BLACK PERSON; DRUG EFFECT; DRUG RESISTANCE; GENETICS; METABOLISM; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION INITIATION; TRANSFORMED CELL LINE;

ADENOVIRUS E1A PROTEINS; AFRICAN CONTINENTAL ANCESTRY GROUP; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TRANSFORMED; CISPLATIN; CLONE CELLS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; HUMANS; INHIBITORY CONCENTRATION 50; MICE; PACLITAXEL; PIPERAZINES; POLYMORPHISM, SINGLE NUCLEOTIDE; RAS PROTEINS; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84981510523     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.1080/15384101.2016.1215390     Document Type: Note

References (16)

1. D.Lane. p53:out of Africa. Genes Dev 2016; 30:876-7; PMID:27083994; http://dx.doi.org/10.1101/gad.281733.116
2. G.A.Azzam, A.K.Frank, M.Hollstein, M.E.Murphy. Tissue-specific apoptotic effects of the p53 codon 72 polymorphism in a mouse model. Cell Cycle 2011; 10:1352-5; PMID:21566457; http://dx.doi.org/10.4161/cc.10.9.15344
3. S.Basu, M.E.Murphy. Genetic Modifiers of the p53 Pathway. Cold Spring Harb Perspect Med 2016; 6:469-81; PMID:27037420; http://dx.doi.org/10.1101/cshperspect.a026302
4. H.J.Kang, Z.Feng, Y.Sun, G.Atwal, M.E.Murphy, T.R.Rebbeck, Z.Rosenwaks, A.J.Levine, W.Hu. Single-nucleotide polymorphisms in the p53 pathway regulate fertility in humans. Proc Natl Acad Sci U S A 2009; 106:9761-6; PMID:19470478; http://dx.doi.org/10.1073/pnas.0904280106
5. C.P.Kung, S.Khaku, M.Jennis, Y.Zhou, M.E.Murphy. Identification of TRIML2, a novel p53 target, that enhances p53 SUMOylation and regulates the transactivation of proapoptotic genes. Mol Cancer Res 2015; 13:250-62; PMID:25256710; http://dx.doi.org/10.1158/1541-7786.MCR-14-0385
6. C.P.Kung, J.I.Leu, S.Basu, S.Khaku, F.Anokye-Danso, Q.Liu, D.L.George, R.S.Ahima, M.E.Murphy. The P72R polymorphism of p53 predisposes to obesity and metabolic dysfunction. Cell Rep 2016; 14:2413-25; PMID:26947067; http://dx.doi.org/10.1016/j.celrep.2016.02.037
7. X.Li, P.Dumont, A.Della Pietra, C.Shetler, M.E.Murphy. The codon 47 polymorphism in p53 is functionally significant. J Biol Chem 2005; 280:24245-51; PMID:15851479; http://dx.doi.org/10.1074/jbc.M414637200
8. M.Jennis, C.P.Kung, S.Basu, A.Budina-Kolomets, J.I.Leu, S.Khaku, J.P.Scott, K.Q.Cai, M.R.Campbell, D.K.Porter, et al. An African-specific polymorphism in the TP53 gene impairs p53 tumor suppressor function in a mouse model. Genes Dev 2016; 30:918-30; PMID:27034505; http://dx.doi.org/10.1101/gad.275891.115
9. G.A.Lang, T.Iwakuma, Y.A.Suh, G.Liu, V.A.Rao, J.M.Parant, Y.A.Valentin-Vega, T.Terzian, L.C.Caldwell, L.C.Strong, et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004; 119:861-72; PMID:15607981; http://dx.doi.org/10.1016/j.cell.2004.11.006
10. K.P.Olive, D.A.Tuveson, Z.C.Ruhe, B.Yin, N.A.Willis, R.T.Bronson, D.Crowley, T.Jacks. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 2004; 119:847-60; PMID:15607980; http://dx.doi.org/10.1016/j.cell.2004.11.004
11. L.Jiang, N.Kon, T.Li, S.J.Wang, T.Su, H.Hibshoosh, R.Baer, W.Gu. Ferroptosis as a p53-mediated activity during tumour suppression. Nature 2015; 520:57-62; PMID:25799988; http://dx.doi.org/10.1038/nature14344
12. F.Kruiswijk, C.F.Labuschagne, K.H.Vousden. p53 in survival, death and metabolic health:a lifeguard with a licence to kill. Nat Rev Mol Cell Biol 2015; 16:393-405; PMID:26122615; http://dx.doi.org/10.1038/nrm4007
13. T.Li, N.Kon, L.Jiang, M.Tan, T.Ludwig, Y.Zhao, R.Baer, W.Gu. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell 2012; 149:1269-83; PMID:22682249; http://dx.doi.org/10.1016/j.cell.2012.04.026
14. C.A.Brady, D.Jiang, S.S.Mello, T.M.Johnson, L.A.Jarvis, M.M.Kozak, D.Kenzelmann Broz, S.Basak, E.J.Park, M.E.McLaughlin, et al. Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression. Cell 2011; 145:571-83; PMID:21565614; http://dx.doi.org/10.1016/j.cell.2011.03.035
15. M.Serrano, A.W.Lin, M.E.McCurrach, D.Beach, S.W.Lowe. Oncogenic ras Provokes Premature Cell Senescence Associated with Accumulation of p53 and p16INK4a. Cell; 88:593-602; PMID:9054499; http://dx.doi.org/10.1016/S0092-8674(00)81902-9
16. V.Vichai, K.Kirtikara. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protocols 2006; 1:1112-6; PMID:17406391; http://dx.doi.org/10.1038/nprot.2006.179